An open-label, randomized, 5-arm, parallel-group study of the effects on viral kinetics, safety and pharmacokinetics of different dosing regimens of Debio 025 in combination with peginterferon alpha-2a and ribavirin in chronic HCV genotype 1 patients who are non responders to standard peginterferon alpha and ribavirin treatment
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Debiopharm
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Planned end date changed from 1 Aug 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 28 Apr 2009 Results presented at the 44th Annual Meeting of the European Association for the Study of Liver, according to a Debiopharm media release.